Quince's Clinical Trial Fails to Meet Key Endpoints
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 29 2026
0mins
Should l Buy QNCX?
Source: stocktwits
- Trial Results Disappoint: Quince's late-stage trial involving 105 patients with Ataxia-Telangiectasia failed to meet its primary endpoint, indicating a lack of statistical significance in treatment efficacy, prompting the company to cease clinical development of its lead asset.
- Stock Price Plummets: Following the announcement of the trial failure, shares of Quince Therapeutics, Inc. (QNCX) closed down 92% on Thursday, reflecting extreme investor pessimism regarding the company's future prospects.
- Market Reaction: Despite the significant drop in stock price, QNCX shares saw a slight 2% increase in after-hours trading, indicating some investor optimism, particularly as retail sentiment on Stocktwits shifted from 'neutral' to 'bullish' over the past 24 hours.
- Industry Context: Ataxia-Telangiectasia is a rare inherited neurodegenerative disorder with no approved therapies globally, despite approximately 4,600 diagnosed patients in the U.S., highlighting a significant unmet medical need in this area.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QNCX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QNCX
Wall Street analysts forecast QNCX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.226
Low
5.00
Averages
7.00
High
10.00
Current: 0.226
Low
5.00
Averages
7.00
High
10.00
About QNCX
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quince Therapeutics Shares Surge After Hours Despite Major Losses
- Significant Stock Volatility: Quince Therapeutics saw a 52.99% increase in after-hours trading to $0.34, despite a 63.03% drop during regular trading to $0.23, indicating market uncertainty about its future prospects.
- Strategic Restructuring Plans: The company has engaged LifeSci Capital as its exclusive financial advisor to assist with restructuring activities and evaluate strategic alternatives, including a reverse merger, aimed at improving its financial standing and addressing market challenges.
- Poor Clinical Trial Results: The NEAT clinical trial did not meet its primary or secondary endpoints, which could negatively impact the market outlook for its lead drug candidate eDSP, further heightening investor concerns.
- Worrisome Financial Position: As of December 31, 2025, the company reported approximately $5.8 million in cash, $11.9 million in short-term investments, and $16.4 million outstanding on its unsecured European Investment Bank line of credit, while facing Nasdaq delisting risks due to its stock price being below $1 since January 29.
See More
Quince Therapeutics Stock Plummets 52% Amid Financial Struggles
- Deteriorating Financial Condition: Quince Therapeutics ended 2025 with only $5.8 million in cash and cash equivalents, $11.9 million in short-term investments, and $16.4 million in unsecured loans, indicating a precarious financial situation that may hinder future operations.
- Consequences of Strategic Review: The company has hired LifeSci Capital as its exclusive financial advisor to explore strategic alternatives, including a potential reverse merger, but the absence of agreements creates uncertainty, potentially leading to further erosion of shareholder value.
- Clinical Trial Failure: Quince's lead candidate eDSP failed to meet primary or secondary endpoints in the NEAT trial, with management confirming that the company has
See More
U.S. Stocks Mostly Higher in Morning Trade, Dow Up Over 200 Points
- Dow Jones Performance: The Dow Jones index rose over 200 points on Thursday, gaining 0.45% to reach 50,348.12, reflecting optimistic market sentiment towards economic recovery, which may attract more investor interest.
- Jobless Claims Data: U.S. initial jobless claims fell by 5,000 to 227,000, below market expectations of 222,000, indicating ongoing improvement in the labor market that could boost consumer confidence.
- Real Estate Sector Recovery: Real estate stocks gained 2.1% on Thursday, reflecting increased market confidence in real estate investments, which may promote further development in related industries.
- Commodity Market Fluctuations: Oil prices fell by 0.8% to $64.09, while gold prices dipped 0.4% to $5,079.00, indicating a cautious investor sentiment in the commodities market that could impact earnings expectations for related companies.
See More
Quince Therapeutics Shares Surge on Strategic Review Announcement
- Strategic Review Drives Stock Surge: Quince Therapeutics has engaged LifeSci Capital to explore strategic options, including potential partnerships and restructuring, leading to a dramatic increase in trading volume exceeding 675 million shares compared to an average of 28 million.
- Positive Market Reaction: While the company cautioned that no specific deal is guaranteed, the market reacted positively, with shares soaring 47.38% to 77 cents, reflecting investor optimism about potential sales or partnerships.
- Technical Indicators Signal Caution: Currently, the stock is trading 51.1% below its 20-day simple moving average and 68.2% below its 50-day SMA, indicating ongoing challenges, with an RSI of 31.15 suggesting neutral territory and a bearish MACD indicating downward pressure.
- Business Model and Market Outlook: Quince Therapeutics focuses on advancing precision therapeutics for rare diseases, and the potential for strategic partnerships could significantly impact its trajectory, with analysts holding mixed views and an average price target of $8.71.
See More
Teradata Quarterly Earnings Beat Expectations
- Strong Earnings Performance: Teradata reported earnings of 74 cents per share, surpassing the analyst consensus estimate of 56 cents, indicating robust profitability that boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $421 million, exceeding the analyst consensus estimate of $400.817 million, suggesting sustained strong market demand that could drive future business expansion.
- Stock Price Surge: Teradata shares jumped 16.5% to $34.07 in pre-market trading, reflecting a positive market reaction to the earnings report, which may attract more investor interest.
- Significant Market Impact: This earnings beat not only lifted the company's stock price but could also positively influence investor sentiment across the industry, further solidifying Teradata's market position in the data analytics sector.
See More
Major U.S. Indices Close Mixed with Notable Stock Movements
- Dow Jones Slightly Up: The Dow Jones Industrial Average rose by 0.1% to close at 50,188.14, indicating a slight optimism in the market despite mixed overall performance across major indices.
- Spotify Stock Surge: Spotify's stock jumped 14.75% to $476.02, with first-quarter revenue guidance of EUR 4.5 billion, reflecting strong user growth and market confidence, as Goldman Sachs reiterated a Buy rating with a $700 price target.
- S&P Global Performance Decline: S&P Global's stock fell 9.71% to $401.08, despite a 9% year-over-year revenue increase to $3.916 billion in Q4, as adjusted EPS slightly missed expectations, leading to diminished investor confidence.
- Intel Stock Drop: Intel's stock decreased by 6.19% to $47.13, reflecting market concerns over future growth, despite a 52-week range of $54.60 to $17.67, indicating significant volatility.
See More
Quince Therapeutics Shares Surge After Hours Despite Major Losses
- Significant Stock Volatility: Quince Therapeutics saw a 52.99% increase in after-hours trading to $0.34, despite a 63.03% drop during regular trading to $0.23, indicating market uncertainty about its future prospects.
- Strategic Restructuring Plans: The company has engaged LifeSci Capital as its exclusive financial advisor to assist with restructuring activities and evaluate strategic alternatives, including a reverse merger, aimed at improving its financial standing and addressing market challenges.
- Poor Clinical Trial Results: The NEAT clinical trial did not meet its primary or secondary endpoints, which could negatively impact the market outlook for its lead drug candidate eDSP, further heightening investor concerns.
- Worrisome Financial Position: As of December 31, 2025, the company reported approximately $5.8 million in cash, $11.9 million in short-term investments, and $16.4 million outstanding on its unsecured European Investment Bank line of credit, while facing Nasdaq delisting risks due to its stock price being below $1 since January 29.
See More
Quince Therapeutics Stock Plummets 52% Amid Financial Struggles
- Deteriorating Financial Condition: Quince Therapeutics ended 2025 with only $5.8 million in cash and cash equivalents, $11.9 million in short-term investments, and $16.4 million in unsecured loans, indicating a precarious financial situation that may hinder future operations.
- Consequences of Strategic Review: The company has hired LifeSci Capital as its exclusive financial advisor to explore strategic alternatives, including a potential reverse merger, but the absence of agreements creates uncertainty, potentially leading to further erosion of shareholder value.
- Clinical Trial Failure: Quince's lead candidate eDSP failed to meet primary or secondary endpoints in the NEAT trial, with management confirming that the company has
See More
U.S. Stocks Mostly Higher in Morning Trade, Dow Up Over 200 Points
- Dow Jones Performance: The Dow Jones index rose over 200 points on Thursday, gaining 0.45% to reach 50,348.12, reflecting optimistic market sentiment towards economic recovery, which may attract more investor interest.
- Jobless Claims Data: U.S. initial jobless claims fell by 5,000 to 227,000, below market expectations of 222,000, indicating ongoing improvement in the labor market that could boost consumer confidence.
- Real Estate Sector Recovery: Real estate stocks gained 2.1% on Thursday, reflecting increased market confidence in real estate investments, which may promote further development in related industries.
- Commodity Market Fluctuations: Oil prices fell by 0.8% to $64.09, while gold prices dipped 0.4% to $5,079.00, indicating a cautious investor sentiment in the commodities market that could impact earnings expectations for related companies.
See More
Quince Therapeutics Shares Surge on Strategic Review Announcement
- Strategic Review Drives Stock Surge: Quince Therapeutics has engaged LifeSci Capital to explore strategic options, including potential partnerships and restructuring, leading to a dramatic increase in trading volume exceeding 675 million shares compared to an average of 28 million.
- Positive Market Reaction: While the company cautioned that no specific deal is guaranteed, the market reacted positively, with shares soaring 47.38% to 77 cents, reflecting investor optimism about potential sales or partnerships.
- Technical Indicators Signal Caution: Currently, the stock is trading 51.1% below its 20-day simple moving average and 68.2% below its 50-day SMA, indicating ongoing challenges, with an RSI of 31.15 suggesting neutral territory and a bearish MACD indicating downward pressure.
- Business Model and Market Outlook: Quince Therapeutics focuses on advancing precision therapeutics for rare diseases, and the potential for strategic partnerships could significantly impact its trajectory, with analysts holding mixed views and an average price target of $8.71.
See More
Teradata Quarterly Earnings Beat Expectations
- Strong Earnings Performance: Teradata reported earnings of 74 cents per share, surpassing the analyst consensus estimate of 56 cents, indicating robust profitability that boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $421 million, exceeding the analyst consensus estimate of $400.817 million, suggesting sustained strong market demand that could drive future business expansion.
- Stock Price Surge: Teradata shares jumped 16.5% to $34.07 in pre-market trading, reflecting a positive market reaction to the earnings report, which may attract more investor interest.
- Significant Market Impact: This earnings beat not only lifted the company's stock price but could also positively influence investor sentiment across the industry, further solidifying Teradata's market position in the data analytics sector.
See More
Major U.S. Indices Close Mixed with Notable Stock Movements
- Dow Jones Slightly Up: The Dow Jones Industrial Average rose by 0.1% to close at 50,188.14, indicating a slight optimism in the market despite mixed overall performance across major indices.
- Spotify Stock Surge: Spotify's stock jumped 14.75% to $476.02, with first-quarter revenue guidance of EUR 4.5 billion, reflecting strong user growth and market confidence, as Goldman Sachs reiterated a Buy rating with a $700 price target.
- S&P Global Performance Decline: S&P Global's stock fell 9.71% to $401.08, despite a 9% year-over-year revenue increase to $3.916 billion in Q4, as adjusted EPS slightly missed expectations, leading to diminished investor confidence.
- Intel Stock Drop: Intel's stock decreased by 6.19% to $47.13, reflecting market concerns over future growth, despite a 52-week range of $54.60 to $17.67, indicating significant volatility.
See More
